Joint Clinical Assessment, JCA
Daraxonrasib (Metastatic pancreatic adenocarcinoma)
Dossier assessment
Indication:
Metastatic pancreatic adenocarcinoma
Timetable
- 3rd quarter, 2026
- Start
Project details
- Project no.
- MP-202623
- Report type
- Joint Clinical Assessment, JCA
- Status
- Commission work started
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
This Joint Clinical Assessment (JCA) is being conducted in cooperation with the Danish Medicines Council, Denmark.
Further background information can be found here: European health technology assessment